Prognostic performance of miR-105 expression in gliomas. A. Among the 76 glioma patients (50 GBMs, 13 AAs and 13 DAs), those with low miR-105 expression (left, solid line, n=47) had significantly shorter survival periods than did patients with high miR-105 expression (right, dotted line, n=29; P≤0.001, log-rank test). B. Among the 63 high-grade glioma patients (50 GBMs and 13 AAs), those with low miR-105 expression (left, solid line, n=47) had significantly shorter survival periods than did patients with high miR-105 expression (right, dotted line, n=16; P≤0.001).